TuHURA Biosciences Inc

TuHURA Biosciences shares its latest breakthroughs—Phase III IFx‑2.0 and early‑stage TBS‑2025—plus a live fireside chat at the H.C. Wainwright BioConnect Investor Conference.

TuHURA Biosciences Inc is a clinical and commercial stage drug development company pioneering innovative cancer treatments and addressing unmet medical needs through its global reach and research efforts.

TuHURA Biosciences Inc. is a rising star in the biotechnology sector, poised to capitalize on its strategic initiatives and scientific advancements in the development of innovative cancer treatments.

TuHURA Biosciences Inc. has secured $15.5 million in funding to advance its cancer research and clinical trials, including a Phase 3 trial for a new treatment for Merkel cell carcinoma.

TuHURA Biosciences, Inc. reported strong first quarter 2025 financial results and provided updates on its Phase 3 immune-oncology trials and acquisition plans.